Finance
Results: 7765-7776 of 44750

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)






